Slide 1. Slide 2. Slide 3. Conflict of Interest. The Role of Pathology/Molecular Diagnostics in Personalized Medicine. NSCLC Landscape Change
|
|
- Evan Pitts
- 6 years ago
- Views:
Transcription
1 Slide 1 The Role of Pathology/Molecular Diagnostics in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments of Pathology and Thoracic/Head & Neck Medical Oncology M. D. Anderson Cancer Center Slide 2 Conflict of Interest Honoraria: Sanofi Aventis, Johnson & Johnson, Genentech, Champions Inc., Roche, AstraZeneca, and Bristol-Myers Squibbs Research Agreements: Genentech, Pfizer, AstraZeneca, Myriad, Eli-Lilly, and Merck. Slide 3 NSCLC Landscape Change Traditional Adenocarcinoma AKT BRAF VEGFR ALK HER2 EPHA/B PDGFR FGFR Unknown INSR Squamous Large Cell Adenocarcinoma EGFR PI3K MAPK KRAS Squamous Cell Ca FGFR1 Amp EGFRvIII Unknown PI3KCA EGFR TK DDR2
2 Maximum Change in Tumor Size (%) Probability of progression-free survival Probability of progression-free survival Slide 4 Lung Cancer Targeted Therapy Landscape Change Histology - Non-squamous 60% Bevacizumab Pemetrexed Adenocarcinoma - EGFR mutation 10% Erlotonib/Gefitinib - ALK-EML4 fusion 3% Crizotinib - MET amplification 20% - PI3KCA mutation 5% - HER2 mutation 1% Squamous Cell Carcinoma - FGFR1 amplification 22% FGFR TKIs - EGFRvIII mutation 5% EGFR TKIs - PI3KCA mutation 4% PI3KCA inhibitors - DDR2 mutation 3% Dasatinib & Nilotinib Slide 5 EGFR Mutations in NSCLC P- loop Extracellular domain C- helix ATP binding N-lobe cleft TK C-lobe Domain Regulatory A- loop domain Deletions - 46% Duplications/ Insertions - 9% L858R - 39% 1.0 IPASS Trial EGFR mut ( + ) EGFR Mut ( - ) Gefitinib (n=132) Carboplatin/Paclitaxel (n=129) 0.8 Gefitinib (n=91) Carboplatin/Paclitaxel (n=85) HR = 0.48 P< HR = 2.85 P< Months Treatment by subgroup interaction test, p< Months Mok TS et al. N Engl J Med 2009;361: Slide 6 EML4-ALK in Lung Adenocarcinoma 2p23 region Histology FISH Protein (IHC) ALK EML Crizotinib in EML4-ALK (+) Progressive disease Partial response Stable disease Complete response 30% ORR: 57% DCR at 8 weeks: 87% Kwak EL et al. N Engl J Med 2010;363:
3 Progression-Free Survival Progression-Free Survival Slide 7 Lung Adenocarcinoma and NSCLC What is new in 2011? All KRAS mutations are not the same Mutations data of a panel of genes (multiplex analysis) are available Gene signatures associated to EGFR TKI response in EGFR wild-type tumors Mechanisms of EGFR TKI resistance Slide 8 KRAS Mutations in Lung Adenocarcinoma Lodish et al Wild Type Codon 12 Codon 13 Base change 1 G 2 G 3 T 1 G 2 G 3 C Amino Acid (replacing Gly) G T (72%) 1 Cys (45%) 1 Cys (5%) 2 Val (20%) G A (14%) 2 Asp (12%) 2 Asp (1%) G C (14%) 2 Ala (9%) T C (2%) 3 Cys (2%) KRAS Mutation Sequencing Codon 12 (G12C) Codon 13 (G13A) G G T G G C T G T G G C G G T G A C Slide 9 BATTLE Trial Novel Findings: Not All KRAS Mutations Are the Same All treatments Cys/Val n=24 Other n=19 Wild n=172 Gene Expression Analysis mut-kras C or V other 0.4 P = Months since randomization Sorafenib Cys/Val n=11 Other n=9 Wild n=66 P = Months since randomization N. Ihle, G. Powis, et al, AACR 2011
4 Slide 10 BATTLE Trial Novel Findings: Not All KRAS Mutations Are the Same Mut-KRAS C or V other RPPA Analysis NSCLC Cell Lines wt-kras K-RAS Akt RalGDS Mek p70s6k mut-kras-g12d mut-kras-g12c K-Ras Akt Mek p70s6k Akt K-RAS RalGDS Mek p70s6k N. Ihle, G. Powis, et al, AACR 2011 Slide 11 Lung Cancer Mutation Consortium GO Grant Panel 1,000 Adenocarcinomas Mutations (8 genes/115 Assays) AKT1 BRAF EGFR HER2 KRAS MEK1 NRAS PIK3CA FISH C-MET amplification EML4-LK fusion Mutation 294 July, ,234 Consented 1,063 Studied Pending FISH 82 B. Johnsons and the LCMC co-investigators, WCLC 2011 Slide 12 Types of Histology and Cytology Specimens Surgical Resection Advanced Tumor Endobronchial Ultrasound (EBUS) or Pleural Fluid Histology Core Needle Biopsy (CNB) Alcohol-fixed Fine Needle Aspiration (FNA) Alcohol-fixed Cell Block Formalin-fixed and Paraffin-embedded (FFPE) Alcohol-fixed
5 Slide 13 Multiplexed Mutation Assays Tumor Tissue Multiplex PCR Resected Specimen Core Biopsy SNaPshot (Applied Biosystem) Mass ARRAY SNP - Sequenom, Inc Dias-Santagata, EMBO Mol Med 2:146, % Sensitivity and ~20ng DNA/multiplex reaction Slide 14 Lung Cancer Mutation Consortium Incidence of Mutations Detected AKT1 NRAS MEK1 MET AMP HER 2 PIK3CA 2% BRAF 2% NO MUTATION DETECTED EML4-ALK 9% EGFR 18% KRAS 23% Mutation found in 54% (280/516) of tumors completely tested B. Johnson. P. Bunn (PI) and the LCMC co-investigators, WCLC 2011 Slide 15 Mutation Analysis by MassARRAY Sequenom - NSCLC Wild-type BRAF (G469-G1406) Mutant (Homozygous) Data Analysis Well Spectrum BRAF (G464-G1391) Wild-type Mutant (Heterozygous) H. Erickson, E. Kim, and I. Wistuba, 2011
6 Slide 16 BATTLE-1 Clinical Trial Platform for future research Clinical trial program (Phase II) Novel trial design Biopsy-mandated study in lung cancer Biomarker discovery Accrual (3 yrs for accrual; Nov 2006 to Oct 2009) Biopsies obtained 324 Patients randomized 255 Patients evaluable 244 Molecular Profiling Frozen tumor: mrna Affymetrix & proteomic (RPPA) Serum and PBMCs Kim et al, Cancer Discovery, April 2011 Slide 17 Erlotinib Personalized Therapy in Advanced NSCLC: BATTLE-1 Schema Vandetanib Patient Enrollment EGFR VEGF Core Biopsy KRAS/BRAF RXR/CyclinD1 Randomization: Equal Adaptive Erlotinib + Bexarotene Primary end point: 8 week Disease Control (DC) Biomarker Profile Sorafenib E. Kim et al, Cancer Discovery 2011 Slide 18 The BATTLE-1 Gene Expression Signatures Scorecard Signature Derived Validation Predictive? Pathway Signatures EGFR KRAS 3 Clinical sets 2 Clinical sets 3 Clinical sets 1 Cell line set 1 Clinical set 1 Cell line set Yes: EGFR mutations Yes: outcome in resected NSCLC with wt EGFR (prognostic) No: erlotinib response in wt EGFR patients Yes: KRAS mutations in BATTLE No: erlotinib response in wt EGFR patients EMT Cell lines 2 Clinical sets Yes: erlotinib DC in wt EGFR Clinical signatures 5 gene WEE BATTLE Cell lines Yes: erlotinib DC in wt EGFR patients Heymach, Saintigny, Byers, Kim, et al, AACR 2011
7 8wDC (%) Probability of survival Signature value Slide 19 5-Gene Signature Predicts 8-wk DC in EGFR Wild-type Tumors BATTLE-1 mrna Profiling (n=139) 8wDC: Yes 8wDC: No NPR3 C5orf23 P<0.001 LCN2 OGG1 TRIM72 P<0.001 P=ns Signature + Signature - Test for interaction P=0.023 Erlotinib Sorafenib arms arm 8wDC 8wDC No Yes Signature - Signature + Log-rank <0.001 HR= CI P=0.001 Median PFS: 12.5 weeks vs. PFS time (months) 7.2 weeks Saintigny et al, AACR 2011 Slide 20 Fig. 1 The frequency of observed drug resistance mechanisms. Mechanisms of Resistance to EGFR TKI Novel Mechanisms T790M Mutation 49% MET amplification 5% PI3KCA Mutation - 5% EMT Changes 5% SCLC Features 14% Unknown 30% Sequist L V et al. Sci Transl Med 2011;3:75ra26-75ra26 Slide 21 Mechanisms of Resistance to EGFR TKI Adenocarcinoma SCLC H&E Synaptophysin H&E Synaptophysin Sequist L V et al. Sci Transl Med 2011;3:75ra26-75ra26
8 Slide 22 Squamous Cell Lung Carcinoma Landscape Change Traditional 2011 Squamous Large Cell Adenocarcinoma Unknown FGFR1 Amp EGFRvIII PI3KCA EGFR TK DDR2 Slide 23 New Target Therapy in Squamous Cell Carcinoma of the Lung Gen Frequency Drug FGFR1 amplification 22% FGFR TKIs EGFRvIII mutation 5% EGFR TKIs PI3KCA mutation 3.6% PI3KCA inhib. EGFR TK mutation 3.4% EGFR TKIs DDR2 mutation 3.2% Dasatanib Nilotinib Okashi and Pao, Cancer Discovery, April 2011 Slide 24 FGFR1 Amplification in Squamous Cell Carcinoma (9%) Weiss J et al. Sci Transl Med 2010;2:62ra93-62ra93
9 Frequency (%) Slide 25 FGFR1 Copy Number Gain (CNG) Analysis by FISH in NSCLC (n=326) Adenocarcinoma (n=217) Squamous Cell (n=89) 20% 17% 13% 11% 7% 1% 4 10 Amplification FGFR1 CNG Tang et al, 2011 Slide 26 FGFR1 Copy Number Analysis by FISH in NSCLC 10 Copies (SCC) Amplification (SCC) 10 Copies (ADCA) 10 Copies (ADCA) Tang et al, 2011 Slide 27 DDR2 Gene Mutations in Squamous Cell Carcinoma of the Lung (3.2%) Hammerman et al, Cancer Discovery April, 2011
10 Slide 28 DDR2 Mutant Tumor Sensitive to Dasatinib Hammerman et al, Cancer Discovery April, 2011 Slide 29 BRAF Inactivating Mutation Associate Sensitive to Dasatinib Tumor BRAF Y472C Mutation B. Sen, and F. Johnson et al, unpublished, 2011 Slide 30 Tissue is the Emperor - For diagnosis, the pathologist needs some! Advanced Tumor Core Needle Biopsy (CNB) Fine Needle Aspiration (FNA) What s the problem? I gave you at least 10 cells!
11 % Reads Mapped WT Seq T/N log Scatterplot: TN IW array vs. TN IW RNAseq (Casewise MD deletion) TN IW RNAseq = * TN IW array Correlation: r = TN IW array 95% confidence Slide 31 Pathology Algorithm of Small Tissue Specimens for Management of Lung Cancer Patients SCLC NSCLC NOS EML4-ALK EGFR FGFR1 Amp DDR2 Mut Panel: MET ampl PI3KCA BRAF HER2 K-, N-, H-RAS MEK AKT NSCLC NOS? IHC: TTF-1 CK 5/7 P63 Small Biopsy Adenocarcinoma Squamous Cell Ca Others EML4-ALK EGFR Panel: MET ampl PI3KCA BRFA HER2 K-, N-, H- RAS MEK AKT FGFR1 Amp DDR2 Mut Panel: PI3KCA BRAF HER2 K-, N-, H-RAS MEK AKT Slide 32 Evolution of Genome Sequencing Technology 1986: Sequencing one genome: Cost = $3 billion Time = 1 decade 2010: Sequencing one genome: Costs = $10 thousand Time = 3 weeks 2012: Sequencing one genome: Cost = $1 thousand Time = 1 week Slide 33 Next Generation of Sequencing NSCLC Core Needle Biopsies (CNB) Frozen CNB: NSCLC 1mm Exome Seq (DNA) Whole Transcriptome (WT-mRNA) Small RNA Seq (mirna) Percentage of WT Reads Mapped: 10 CNB vs. 10 Resected NSCLCs Correlation of WT Seq and mrna Array Profiling of 11 NSCLCs r=0.48 P=10-8 TN IW RNAseq CNB Resected Microarray T/N log2 Wistuba et al, unpublished, 2011
12 Slide 34 Molecular Pathology of Lung Cancer: 2011 New actionable genetic abnormalities continued to be discovered in NSCLC In lung adenocarcinoma and NSCLC: All KRAS mutations are not the same ~50% of tumors have actionable gene mutations Gene expression signatures predict response to EGFR TKI in EGFR wild-type tumors Novel mechanisms and changes associated to EGFR TKI resistance Squamous cell carcinoma shows distinct genetic abnormalities: FGFR1 amp and DDR2 mutations Next generation sequencing shows a promise for application to clinical settings Slide 35 Acknowledgements MD Anderson Cancer Center Thoracic Molecular Pathology Lab Heidi Erickson Hector Galindo Nana Hanson Christina McDowell Annette Basey Chi-Wan Chow Zuoming Chu Junya Fujimoto Lakshmi Kakarala MD Anderson Cancer Center Edward Kim (Medical Oncology) Waun Ki Hong (Medical Oncology) Roy Herbst (Medical Oncology) John Heymach (Medical Oncology) Scott Lippman (Medical Oncology) Gordon Mills (System Biology) Katherine Stemke-Hale (System Biology) Cesar Moran (Pathology) Neda Kalhor (Pathology) Jack Lee (Biostatistics) Support US Department of Defense BATTLE and PROSPECT, Stading Family, Cohen- Reinauch BATTLE-2 Fund and V Foundation
The Role of Pathology/Molecular Diagnostics in Personalized Medicine
The Role of Pathology/Molecular Diagnostics in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationThe Role of Pathology/Molecular Diagnostics in Personalized Medicine
The Role of Pathology/Molecular Diagnostics in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationThe Role of Pathology/Molecular Diagnostic in Personalized Medicine
The Role of Pathology/Molecular Diagnostic in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSlide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/3/75/75ra26/dc1 Supplementary Materials for Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia V. Sequist,*
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationand management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
More informationAdditional clinical features of this patient include:
*Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationIndividualized therapy in lung cancer Where are we in 2012?
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationSelecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationPathologists role Ancillary Studies in Cytology Challenges. Pre-analytical issues. LUNG CYTOLOGY Predictive markers and molecular tests
Pathologists role LUNG CYTOLOGY Predictive markers and molecular tests Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Pathology Unit, IPATIMUP
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationMolecular Diagnostics in Lung Cancer
Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,
More informationLongcarcinoom nieuwe wegen nieuwe kwaliteitsaspecten. Erik Thunnissen Pathologie Vumc, Amsterdam,NL
Longcarcinoom nieuwe wegen nieuwe kwaliteitsaspecten Erik Thunnissen Pathologie Vumc, Amsterdam,NL e.thunnissen@vumc.nl LUNG CANCER Diagnostic, Predictive flow Cancer in the lung: primary vs metastases
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More information1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationMECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D.
MECHANISMS OF 1ST GENERATION RESISTANCE Byoung Chul Cho, M.D., Ph.D. CONFLICT OF INTEREST Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST Consulting role: Novartis, AstraZeneca,
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationAn overview of the design and conduct of the BATTLE trials
Review Article Page 1 of 13 An overview of the design and conduct of the BATTLE trials Suyu Liu, J. Jack Lee Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas,
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationSolange Peters, MD-PhD Cancer Center, Lausanne Switzerland EGFR AND NSCLC
Solange Peters, MD-PhD Cancer Center, Lausanne Switzerland EGFR AND NSCLC Interactive Clinical Case History Maria José 1963 Since end 2010, progressive dyspnea Attends Emergency Room 02.01.2011 after 3
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationDevelopments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA
Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Geneva April 20, 2012 Neuroendocrine tumors of lung Typical
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationStatistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets
Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets Bibhas Chakraborty, PhD Centre for Quantitative Medicine, Duke-NUS March 29, 2015 Personalized or Precision Medicine
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationMolecular classification of lung cancer for clinical practice
Centre Jean Perrin Centre de Lutte contre le Cancer d'auvergne Clermont-Ferrand - France - Molecular classification of lung cancer for clinical practice Frédérique Penault-Llorca In the beginning.. There
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationPATHOLOGY WEBINAR. SESSION 2: March 20th, David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center.
PATHOLOGY WEBINAR SESSION 2: March 20th, 2017 David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center James Suh, MD Associate Medical Director and Molecular Pathologist/Foundation Medicine
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationWINTHER: GUSTAVE ROUSSY GUSTAVE ROUSSY. NOM DU DOCUMENT / Date
WINTHER Study Jean-Charles Soria, Razelle Kurzrock, Josep Tabernero, Apostolia Tsimberidou, Jordi Rodon, Raanan Berger, Amir Onn, Gerald Batist, Eitan Rubin, Yohann Loriot, Catherine Bresson, Vladimir
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationRediscovering non-small cell lung cancer -Heterogeneity and more heterogeneity-
Rediscovering non-small cell lung cancer -Heterogeneity and more heterogeneity- D. Ross Camidge, MD PhD Director, Thoracic Oncology Clinical Program University of Colorado 5 th Annual Bonnie J. Addario
More informationMOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationMolecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationEvolución Clonal de los Tumores y Biopsia Líquida en Cáncer de Pulmón
Evolución Clonal de los Tumores y Biopsia Líquida en Cáncer de Pulmón Ignacio I. Wistuba, M.D. Professor and Chair Department of Translational Molecular Pathology The University of Texas M. D. Anderson
More informationEGFR. Pathway and biomarkers. Alex Soltermann
EGFR Pathway and biomarkers Alex Soltermann EGFR = HER1 signaling pathway EGFR Cheng Mod Pathol 2012 Chromosome 7p11.2, spans 200kb, 28 exons, 464 aa, 170 kda protein 2 Signal transduction pathways controlled
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationA Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More information